Evidence-Based Medicine Guidelines
Tamoxifen vs aromatase inhibitors in premenopausal early breast cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Tamoxifen Vs Aromatase Inhibitors in Premenopausal Early Breast Cancer." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451167/all/Tamoxifen_vs_aromatase_inhibitors_in_premenopausal_early_breast_cancer.
Tamoxifen vs aromatase inhibitors in premenopausal early breast cancer. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/451167/all/Tamoxifen_vs_aromatase_inhibitors_in_premenopausal_early_breast_cancer. Accessed December 5, 2025.
Tamoxifen vs aromatase inhibitors in premenopausal early breast cancer. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/451167/all/Tamoxifen_vs_aromatase_inhibitors_in_premenopausal_early_breast_cancer
Tamoxifen Vs Aromatase Inhibitors in Premenopausal Early Breast Cancer [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 December 05]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451167/all/Tamoxifen_vs_aromatase_inhibitors_in_premenopausal_early_breast_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tamoxifen vs aromatase inhibitors in premenopausal early breast cancer
ID - 451167
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451167/all/Tamoxifen_vs_aromatase_inhibitors_in_premenopausal_early_breast_cancer
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
